Status: Bibliographieeintrag
Standort: ---
Exemplare:
---
| Online-Ressource |
Verfasst von: | Sund, Fredrik [VerfasserIn]  |
| Tufveson, Gunnar [VerfasserIn]  |
| Döhler, Bernd [VerfasserIn]  |
| Opelz, Gerhard [VerfasserIn]  |
| Eriksson, Britt-Marie [VerfasserIn]  |
Titel: | Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients |
Titelzusatz: | a 10-year experience |
Verf.angabe: | Fredrik Sund, Gunnar Tufveson, Bernd Döhler, Gerhard Opelz and Britt-Marie Eriksson |
Jahr: | 2013 |
Umfang: | 8 S. |
Fussnoten: | Advance access publication 14 December 2012 ; Gesehen am 27.01.2022 |
Titel Quelle: | Enthalten in: Nephrology, dialysis, transplantation |
Ort Quelle: | Oxford : Oxford Univ. Press, 1986 |
Jahr Quelle: | 2013 |
Band/Heft Quelle: | 28(2013), 3, Seite 758-765 |
ISSN Quelle: | 1460-2385 |
Abstract: | Cytomegalovirus (CMV) remains an important pathogen in transplant patients, and valacyclovir (VACV) prophylaxis 8 g/day has been used in high-risk CMV-seromismatched [D+/R−] renal transplant patients to decrease CMV disease. Neurotoxic adverse effects have limited its use, and the aim of the present study was to retrospectively evaluate low-dose VACV prophylaxis, 3 g/day for 90 days after transplantation, in 102 D+/R− renal transplant patients.We compared patient and graft survival rates up to 5 years after transplantation with the data from the Collaborative Transplant Study Group (CTS) database. The incidence of CMV disease, rejection and neurotoxic adverse effects was analyzed up to 1 year after transplantation.The patient and graft survival rates up to 5 years were comparable with those derived from the CTS. CMV disease was diagnosed in 25% of the patients and 2% developed tissue-invasive CMV disease. The rejection frequency was 22% and neurotoxic adverse effects were seen in 2% of the patients.Low-dose VACV prophylaxis (3 g/day) for 90 days post-transplantation results in high patient and graft survival rates and reduces the incidence of CMV disease. Neurotoxic adverse effects are minimal. We believe that low-dose VACV prophylaxis should be considered to form one of the arms in future prospective comparison studies for the prevention of CMV disease in the high-risk D+/R− population of renal transplant patients. |
DOI: | doi:10.1093/ndt/gfs531 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1093/ndt/gfs531 |
| DOI: https://doi.org/10.1093/ndt/gfs531 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1787289613 |
Verknüpfungen: | → Zeitschrift |
Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients / Sund, Fredrik [VerfasserIn]; 2013 (Online-Ressource)
68871338